Celmatix Clinical Laboratories, a subsidiary of digital health technology industry leader Celmatix, has established its new laboratory at the New Jersey Economic Development Authority’s (EDA) Commercialization Center for Innovative Technologies (CCIT) in North Brunswick.
Celmatix was founded to create products that bring greater clarity to the treatment of infertility and pave the way for women to proactively manage their fertility throughout their reproductive life, according to a statement prepared by the EDA. Through its products, Celmatix strives to use big data analytics and genomics to help clinics optimize patient outcomes and enhance the patient experience.
Celmatix recently announced Fertilome, the world’s first multigene panel test that reveals how a woman’s DNA may affect her reproductive health. The test is available through physicians and gives women unique genetic insights, allowing them to make more informed, proactive reproductive health decisions.
Companies interested in touring CCIT should visit www.njeda.com/CCIT or contact Lenzie Harcum at lharcum@njeda.com.
